<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765934</url>
  </required_header>
  <id_info>
    <org_study_id>RapydanClinicalChemistry</org_study_id>
    <nct_id>NCT00765934</nct_id>
  </id_info>
  <brief_title>Influence of Rapydan on Clinical Chemistry and Hematology Measurements</brief_title>
  <official_title>Does Rapydan Influence Routine Clinical Chemistry and Hematology Measurements?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LabNoord</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LabNoord</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is an increasing awareness of the importance of treating procedure-related pain.
      Patients undergoing vascular access procedures are often afraid of needles and the discomfort
      associated with injections. This type of pain and/or fear can be stressful to patients. [1]
      For prevention of the pain associated with these procedures, the hospital is using Rapydan
      plasters. Rapydan consists out of two local anesthetics: lidocaine and tetraca√Øne. Rapydan
      produces topical anesthesia after an application time of 30 minutes and is used in the
      Martini Hospital for pain relieve by venipuncture and IV cannulation. The venous blood
      draining the anaesthetized skin contains a higher blood concentration of the local
      anesthetics than does venous blood in other parts of the body [2] Although the concentrations
      of the local anesthetics are low in patients with normal skin, the question is whether the
      presence of the local anesthetics which Rapydan contains might influence routine measurements
      in clinical chemistry and hematology.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Routine Clinical Chemistry measurements differences</measure>
    <time_frame>1</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Rapydan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Internal control. Blood from both arms will be drawn. Only one arm of the subject is treated with Rapydan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapydan</intervention_name>
    <description>lidocaine / tetracaine 70/70 mg patch</description>
    <arm_group_label>Rapydan</arm_group_label>
    <other_name>Lidocaine Tetracaine Patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Volunteers 20-60 years who are decision making competent

        Exclusion Criteria:

        Patients with local anesthetic allergy Patients using antiarrhythmic drugs Patients using
        other local anesthetics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Oude Elferink, MSc</last_name>
    <role>Study Director</role>
    <affiliation>LabNoord</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LabNoord</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Curry SE, Finkel JC. Use of the Synera patch for local anesthesia before vascular access procedures: a randomized, double-blind, placebo-controlled study. Pain Med. 2007 Sep;8(6):497-502.</citation>
    <PMID>17716323</PMID>
  </reference>
  <reference>
    <citation>Amdisen A, Glud V. No influence from topical application of EMLA cream before blood sampling on routine clinical chemistry and haematology measurements. Eur J Clin Pharmacol. 1991;41(6):619-20.</citation>
    <PMID>1815978</PMID>
  </reference>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2008</study_first_submitted>
  <study_first_submitted_qc>October 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2008</study_first_posted>
  <last_update_submitted>May 17, 2010</last_update_submitted>
  <last_update_submitted_qc>May 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>R.F.M. Oude Elferink</name_title>
    <organization>LabNoord</organization>
  </responsible_party>
  <keyword>Healthy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Tetracaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

